Short Interest in Moleculin Biotech, Inc. (NASDAQ:MBRX) Rises By 23.4%

Moleculin Biotech, Inc. (NASDAQ:MBRX) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 572,100 shares, an increase of 23.4% from the March 15th total of 463,600 shares. Based on an average trading volume of 5,380,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 4.1% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Moleculin Biotech in a research report on Monday, March 24th. Maxim Group raised shares of Moleculin Biotech from a “hold” rating to a “buy” rating and set a $4.00 price target on the stock in a research report on Tuesday, March 25th. Finally, StockNews.com upgraded shares of Moleculin Biotech to a “sell” rating in a research note on Wednesday, March 26th.

Moleculin Biotech Trading Down 4.8 %

Shares of Moleculin Biotech stock traded down $0.04 on Friday, reaching $0.87. 271,414 shares of the company were exchanged, compared to its average volume of 1,440,134. Moleculin Biotech has a one year low of $0.40 and a one year high of $5.47. The company has a 50-day moving average of $1.10 and a 200 day moving average of $1.78.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.